Medpace Holdings Inc. Common Stock (MEDP)
Stock · NASDAQ · Health Care
$618.31as of 10/16/2026
Price chart
Active signals
MEDP Signal Track Record
How signals performed across all stocks →What MEDP's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 35 | +1.5% | 54% | September 15, 2026 |
| Bollinger Band Breakout | 28 | +0.8% | 54% | August 21, 2026 |
| Bollinger Band Breakdown | 16 | +3.3% | 56% | April 23, 2026 |
| 200-Day Moving Average TouchActive now | 14 | +1.9% | 50% | June 24, 2026 |
| Any 20-session window (baseline) | +3.0% | 63% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About MEDP
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries;…
- Sector
- Health Care
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Employees
- 6,500
- Website
- investor.medpace.com/
Fundamentals
- 1-day range
- $618.88$632.33
- Market cap
- $16.33B
- P/E (trailing)
- 35.88
- P/E (forward)
- 32.10
- EPS (trailing)
- $17.05
- Dividend yield
- —
- Beta
- 1.11
- Avg. volume
- 271.2K
How Medpace Holdings Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 10, 2026 · via SEC EDGAR / Finnhub
Forecasts
13 analyst ratings
Medpace Holdings Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- MEDPMedpace Holdings Inc. Common Stock$618.47▼ 1.61%Market cap $16.33BP/E 35.88$373$677.9
- CRLCharles River Laboratories International Inc. Common Stock$300.15▼ 1.99%Market cap $12.79BP/E —$146.2$333.3
- ICLRICON plc Ordinary Shares$170.18▼ 2.83%Market cap $12.34BP/E 190.41$66.57$203.91
- INCYIncyte Corp. Common Stock$113.07▼ 0.18%Market cap $24.00BP/E 14.30$84.02$132.6
- ABSIAbsci Corporation Common Stock$8.25▼ 7.09%Market cap $1.29BP/E —$2.24$12.06
- NRCNRC Health Common Stock$20.15▼ 4.55%Market cap $430.67MP/E 79.70$11.01$23.68
- OABIOmniAb Inc. Common Stock$4.59▼ 2.96%Market cap $324.74MP/E —$1.3$5.43
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| MEDP Medpace Holdings Inc. Common Stock | $16.33B | 35.88 | $618.47 | ▼ 1.61% | $373$677.9 |
| CRL Charles River Laboratories International Inc. Common Stock | $12.79B | — | $300.15 | ▼ 1.99% | $146.2$333.3 |
| ICLR ICON plc Ordinary Shares | $12.34B | 190.41 | $170.18 | ▼ 2.83% | $66.57$203.91 |
| INCY Incyte Corp. Common Stock | $24.00B | 14.30 | $113.07 | ▼ 0.18% | $84.02$132.6 |
| ABSI Absci Corporation Common Stock | $1.29B | — | $8.25 | ▼ 7.09% | $2.24$12.06 |
| NRC NRC Health Common Stock | $430.67M | 79.70 | $20.15 | ▼ 4.55% | $11.01$23.68 |
| OABI OmniAb Inc. Common Stock | $324.74M | — | $4.59 | ▼ 2.96% | $1.3$5.43 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Mizuho Maintains Outperform on Medpace Holdings, Raises Price Target to $700benzinga · 10/7/2026
- Mizuho Maintains Outperform on Medpace Holdings, Raises Price Target to $700Benzinga · 10/7/2026
- Barclays Maintains Equal-Weight on Medpace Holdings, Raises Price Target to $625Benzinga · 10/7/2026
- Medpace (MEDP) Stock Declines While Market Improves: Some Information for InvestorsYahoo · 10/6/2026
- Here’s How Much You Would Have Made Owning Medpace Holdings Stock In The Last 10 YearsBenzinga · 10/6/2026
- Medpace Holdings President & CEO Trades $30.32M In Company StockBenzinga · 10/2/2026
- 'HHS launches project to speed up clinical trials' - AxiosBenzinga · 9/30/2026
- Here's How Much $100 Invested In Medpace Holdings 10 Years Ago Would Be Worth TodayBenzinga · 9/30/2026
- UBS Upgrades Medpace Holdings to Neutral, Raises Price Target to $673Benzinga · 9/30/2026
Insider Activity
Insider Actions →- Susan E. Burwig · October 7, 2026 · Option Exercise2.0K @ $166.73
- Cornelius P. McCarthy III · September 30, 2026 · Option Exercise28
- Brian T. Carley · September 30, 2026 · Option Exercise36
- Robert O. Kraft · September 30, 2026 · Option Exercise32
- August J. Troendle · September 30, 2026 · Sale22.0K @ $625.47
- August J. Troendle · September 29, 2026 · Sale26.7K @ $621.02
- August J. Troendle · September 28, 2026 · Sale2.4K @ $620.07
- August J. Troendle · September 25, 2026 · Sale154 @ $620.6
- August J. Troendle · September 24, 2026 · Sale27.8K @ $621.33
- August J. Troendle · September 23, 2026 · Sale16.1K @ $628.64
- August J. Troendle · September 22, 2026 · Sale49.0K @ $628.11
- August J. Troendle · September 21, 2026 · Sale21.9K @ $623.29
- August J. Troendle · September 17, 2026 · Sale10.9K @ $620.4
- August J. Troendle · September 16, 2026 · Sale8.8K @ $621.29
- Susan E. Burwig · September 15, 2026 · Option Exercise3.0K @ $166.73
Institutional Ownership
March 31, 2026
- Total shares held
- 22.56M
- Total value held
- $10.08B
- Institutional holders
- 715
- Unknown2.47M
- Unknown1.35M
- Unknown1.01M
- Unknown773.9K
- Unknown745.1K
- Unknown682.2K
- Unknown577.6K
- Unknown504.7K
- Unknown503.2K
- Unknown446.1K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Medpace sees strong bookings but faces valuation and growth concerns
Recent analyst articles note that Medpace reported strong bookings, which support its technical momentum. At the same time, several pieces point out that the company's high valuation and flat pass‑through growth leave limited upside, and that a shorter, cleaner backlog may be misinterpreted as a smaller pipeline. These factors together shape the current market view of the stock.
Medpace sees strong bookings but faces valuation and growth concerns. Recent analyst articles note that Medpace reported strong bookings, which support its technical momentum. At the same time, several pieces point out that the company's high valuation and flat pass‑through growth leave limited upside, and that a shorter, cleaner backlog may be misinterpreted as a smaller pipeline. These factors together shape the current market view of the stock.